Displaying drugs 15001 - 15025 of 15142 in total
CRA_1802
Experimental
CRA_10972
Experimental
CRA_11092
Experimental
REN-850
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
Lactaldehyde
Experimental
RAF-265
Investigational
Dibromothymoquinone
At low concentrations, this compound inhibits reduction of conventional hydrophilic electron acceptors, probably acting as a plastoquinone antagonist. At higher concentrations, it acts as an electron acceptor, intercepting electrons either before or at the site of its inhibitory activity. [PubChem]
Experimental
PROPYL-1-PHOSPHATE
Experimental
PH94B
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
AP5346
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
Terevalefim
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
(S)-acetoin
A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Experimental
(R)-acetoin
A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Experimental
Betaine aldehyde
Experimental
3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol
Experimental
Tin protoporphyrin IX
Investigational
2,3-Dimethyl-1,4-naphthoquinone
Experimental
P-Hydroxybenzaldehyde
Experimental
1-Amino-1-Carbonyl Pentane
Experimental
Acetophenone
Experimental
Atl146e
ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Investigational
Displaying drugs 15001 - 15025 of 15142 in total